Oxford BioDynamics PLC Director/PDMR Shareholding (2147Q)
15 February 2019 - 9:01PM
UK Regulatory
TIDMOBD
RNS Number : 2147Q
Oxford BioDynamics PLC
15 February 2019
15 February 2019
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
PDMR Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it today
received notice that Vulpes Life Sciences Fund, which is controlled
by Non-Executive Director, Steven Diggle, has purchased 22,000
Ordinary Shares of 1 pence each at an average price of GBP1.684 per
share.
Following this transaction, Vulpes Life Sciences Fund is
interested in 11,613,883 Ordinary Shares, representing
approximately 12.55% of the Company's current issued share
capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Steven Diggle
------------------------------- --------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status Director/PDMR
------------------------------- --------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Oxford BioDynamics Plc
------------------------------- --------------------------------------
b) LEI 2138005Y1TK258O5U928
------------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument,
type of instrument ISIN: GB00BD5H8572
Identification code
------------------------------- --------------------------------------
b) Nature of the transaction Acquisition of ordinary shares
------------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1.685 17,000
----------
1.680 5,000
----------
------------------------------- --------------------------------------
d) Aggregated information Price Volume
- Aggregated volume 1.684 22,000
- Price -------
------------------------------- --------------------------------------
e) Date of the transaction 13 and 14 February 2019
------------------------------- --------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- --------------------------------------
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
Stephane Auton
Edward Mansfield +44 (0)20 7408 4090
FTI Consulting
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLIFEAFRIELIA
(END) Dow Jones Newswires
February 15, 2019 05:01 ET (10:01 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024